Clinical Read2026-06-12
EPKINLY/Epcoritamab-bysp (GEN3013) (CD3xCD20 Bispecific)
AbbVieABBV
- Indication
- Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
- Stage
- Phase 3
- Event
- Phase 3 Data readout
- Details
01/16/26:- Ph3 EPCORE DLBCL-1 topline showed PFS benefit, no OS benefit; detailed data at future meeting. 06/08/26:- EPCORE DLBCL-1 Ph3 PFS and safety results to be presented at EHA 2026 June 12.
- Source
- View catalyst source ↗
Financial Snapshot
Market Cap
$394.1B
Price
$225.42